

ITM Announces Transfer of Non-dilutive Debt Financing from Blue Owl Managed Funds to Perceptive Advisors

Garching / Munich, June 12, 2026 – [ITM Isotope Technologies Munich SE \(ITM\)](#), a leading radiopharmaceutical biotech company, today announced that its [non-dilutive debt financing with Blue Owl Managed Funds](#) of up to USD 262.5m was transferred to [Perceptive Advisors](#), a leading life sciences investment firm. Additional details of the transfer agreement were not disclosed.

“Perceptive’s deep expertise and long-standing commitment to investing in global life sciences is a strong fit for ITM’s next phase of growth. Their dedication to supporting the advancement of impactful medicines aligns with our mission to deliver novel radiopharmaceutical solutions to improve outcomes for people living with cancer,” said **Dr. Klaus Maleck, chief financial officer of ITM**.

“Perceptive is dedicated to backing biotech companies pioneering transformative innovation in healthcare. We recognize the significant potential of radiopharmaceuticals as a breakthrough in precision oncology and ITM is making important headway in advancing this field,” added **Sam Chawla, portfolio manager, Perceptive Advisors**.

About ITM Isotope Technologies Munich SE

ITM, a leading radiopharmaceutical biotech company, is dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors. We aim to meet the needs of cancer patients, clinicians and our partners through excellence in development, production and global supply of medical radioisotopes. With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple Phase 3 studies, combining the company’s high-quality radioisotopes with a range of targeting molecules. By leveraging our two decades of pioneering radiopharma expertise, central industry position and established global network, ITM strives to provide patients with more effective targeted treatment to improve clinical outcome and quality of life. www.itm-radiopharma.com

About Perceptive Advisors

Founded in 1999, Perceptive Advisors focuses on supporting progress in the life sciences industry by identifying opportunities and directing financial resources toward the most promising technologies in modern healthcare. Today, the firm manages approximately \$8 billion across our strategies as of October 22, 2025.

ITM Contact

Corporate Communications

Kathleen Noonan/Julia Westermeir

Phone: +49 89 329 8986 1500

Email: communications@itm-radiopharma.com

Investor Relations

Ben Orzelek

Phone: +49 89 329 8986 1009

Email: investors@itm-radiopharma.com